KBC Group
DNTH icon

KBC Group’s Dianthus Therapeutics DNTH Stock Holding History

KBC Group’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$87K Hold
987
– – ﹤0.01% 1475
2026
Q2 		$96K Buy
+987
New +$86.2K ﹤0.01% 1443
2025
Q1 		– Sell
-1,593
Closed -$35K – 1882
2024
Q4 		$35K Buy
+1,593
New +$41K ﹤0.01% 1826

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

KBC Group's DNTH Position: Q3 2026 in Review

KBC Group held its Dianthus Therapeutics (DNTH) position steady in Q3 2026 at 987 shares worth $87K. The position accounts for ﹤0.01% of the portfolio, ranked #1475.

KBC Group first reported a position in DNTH in Q4 2024 and has held it in 3 quarters since. The position peaked at $96K in Q2 2026. 188 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • KBC Group held 987 shares of Dianthus Therapeutics worth $87K as of Q3 2026.
  • KBC Group left its Dianthus Therapeutics share count unchanged in Q3 2026.
  • Dianthus Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1475 holding.
  • KBC Group first reported a position in Dianthus Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • KBC Group's Dianthus Therapeutics position peaked at $96K in Q2 2026.
  • 188 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.